anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Mandibular fractures are common in maxillofacial trauma, often requiring surgical intervention for optimal recovery. One critical concern during such procedures is the potential for nerve damage, specifically involving the mandibular canal. This study aims to investigate whether the presence of postoperative mandibular canal discontinuity is associated with an increased risk of nerve damage.
METHODOLOGY: A retrospective analysis was conducted on a cohort of 72 postoperative mandibular fracture patients. In total, 58 patients had entire mandibular canal continuity, while 14 showed discontinuity. Clinical records and follow-up data were examined to assess the occurrence of nerve injury. Statistical analysis was performed to determine the significance of any correlation.
RESULTS: Of the 14 patients with mandibular canal discontinuity, 9 (64.28%) exhibited paresthesia. In patients where mandibular canal continuity was maintained, 5 (8.62%) patients reported paresthesia. These results suggest a higher incidence of paresthesia in patients with mandibular canal discontinuity, albeit with a small sample size. Notably, only 3 patients in the discontinuity group did not show any sign of improvement, while the remaining patients in both groups demonstrated complete recovery in 6 months of follow-up period.
DISCUSSION: The findings suggest a potential link between mandibular canal discontinuity and an increased risk of paresthesia in postoperative mandibular fracture patients. It is hypothesized that discontinuity may lead to nerve compression, irritation, or direct damage during healing. The observed complete recovery in most patients, including those with paresthesia, highlights the potential for the nervous system to repair itself over a period of time. However, further studies with larger sample sizes are warranted to establish a more definitive correlation.
CONCLUSION: This study provides preliminary evidence that mandibular canal discontinuity may contribute to a higher incidence of paresthesia in postoperative mandibular fracture patients. Clinicians should be cautious when addressing mandibular fractures to minimize the risk of nerve damage, particularly in cases involving canal discontinuity. The encouraging trend of complete recovery among the majority of patients suggests a positive prognosis for nerve healing.
Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontaneously, to progressive disseminated forms that can be debilitating and sometimes life-threatening. The rare histiocytic disorders (RHD), or non-Langerhans cell disorders, are a diverse group of disorders defined by the accumulation of histiocytes that do not meet the criteria for Langerhans cell histiocytosis (LCH) or hemophagocytic lymphohistiocytosis (HLH). They include: Juvenile xanthogranuloma family, Erdheim-Chester disease, Multifocal Reticulohistiocytosis, Rosai-Dorfman disease and the Malignant Histiocytoses. Since they are so rare, there is limited understanding of their causes and treatments. Physicians, patients and parents of children with rare histiocytoses frequently consult members of the Histiocyte Society on the management of these disorders. Very often, no specific recommendation about treatment can be made due to the lack of prospective outcome data for these rare entities. The creation of an International Rare Histiocytic Disorders Registry (IRHDR) will facilitate a uniform diagnosis of the RHD's, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry will also provide expert pathology reviews and may lead to future therapeutic recommendations. Furthermore, the IRHDR can provide a framework for future clinical trials, thus, creating excellent research opportunities. Lastly, a de-identified link between clinical data and companion biology studies can potentially be accomplished in the future through the IRHDR. This may further help in understanding the etiology of these rare diseases, as well as identifying potential therapeutic targets.
FIELD: biotechnology. 
     SUBSTANCE: inventions group relates to the field of biotechnology. The proposed vaccine against swine streptococcosis, polyvalent inactivated, contains the following components per one immunizing dose of the drug (2 cm 3 ): formalin-inactivated protective antigens of Streptococcus suis strains No. UR-4-VBH - 3.5 billion mcr. cl.; Streptococcus porcinus UR-3-VBH - 3.5 billion mcr. cl.; Streptococcus pyogenes OB-4-VBH - 3.5 billion mcr. cl.; Streptococcus dysgalactiae UR-16-VBKh - 3.5 billion mcr. cl., as well as pharmaceutically acceptable target additives. The method for obtaining a vaccine includes the cultivation of industrial strains; inactivation of the culture fluid; concentration of antigens; determination of the completeness of antigen inactivation; preparation of a vaccine batch; control of the sterility of the vaccine and the safety of the vaccine; determination of the immunogenic and antigenic activity of the vaccine. The vaccine is used as a prophylactic agent when administered to pregnant sows intramuscularly in the upper third of the neck (behind the ear) in a dose of 2 ml twice: the first time - 50-55 days before farrowing, the second time - 25-30 days before farrowing. Subsequently, the vaccine is administered 25-30 days before each subsequent farrowing once in the same dose. It is not allowed to vaccinate sows later than 25-30 days before farrowing, as well as lactating animals. Piglets are vaccinated starting at 14 days of age. The vaccine is injected intramuscularly into the femoral muscle group twice with an interval of 21-24 days at a dose of 2 ml, additional revaccination is carried out at the age of 4 months. once. 
     EFFECT: vaccine has enhanced immunogenic and antigenic activity, induces intense and long-term immunity in pigs against streptococcosis caused by S. suis, S. dysgalactiae, S. porcinus and S. pyogenes species, which significantly distinguishes it from the existing vaccines of this direction. 
     8 cl, 5 tbl, 7 ex
The invention discloses an antibody for detecting coronavirus and application thereof, wherein the antibody comprises three heavy chain complementarity determining regions and three light chain complementarity determining regions, and the amino acid sequences of the heavy chain complementarity determining regions CDR1, CDR2 and CDR3 are shown as SEQ ID NO: 2. 3 and 4, the amino acid sequences of the light chain complementarity determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO: 10. 11, 12. The antibody further comprises four heavy chain variable framework regions and four light chain variable framework regions, wherein the amino acid sequences of the heavy chain variable framework regions FR1, FR2, FR3 and FR4 are respectively shown in SEQ ID NO: 5. 6, 7 and 8, and the amino acid sequences of the light chain variable framework regions FR1, FR2, FR3 and FR4 are respectively shown as SEQ ID NO: 13. 14, 15, 16. The antibody can be specifically combined with coronavirus antigens or variant strains thereof, and has high combination activity.
This pilot study will recruit 40 patients with Major Depression and a history of at least two failed prior adequate somatic treatments. In addition to usual physical work-up, all patients will have extensive thyroid testing, and then will receive standard dose Tranylcypromine (i.e., max. 60 mg/d). Non-remitters will have dose increased to max. 120 mg/d if tolerated. Non-remitters to high dose Tranylcypromine will then have Dextroamphetamine added with frequent blood pressure monitoring to max. 40 mg/d. Non-remitters will have Triiodothyronine added to the Tranylcypromine.
A composition of matter that when applied topically relieves pain in the area where it is applied (i.e. knees, back, elbows, heels, etc.). The composition contains chitosan, canola oil, sea salt minerals (chloride ion, sulfate ion, calcium, potassium, zinc, sodium, magnesium and nickel), and water. To make the composition, the ingredients should be at room temperature. Dissolve 7-8 grams of medical grade or edible grade chitosan in 1 liter of canola oil. Dissolve 2 tsp of sea salt containing the following minerals (chloride ion, sulfate ion, calcium, potassium, zinc, sodium, magnesium and nickel) in 50ml of distilled water. Pour the sea salt solution into the chitosan-canola oil mixture. The chitosan-canola oil is hydrophilic and absorbs the sea salt water into the composition negating the water-oil interface. Shake well for 10 minutes or mechanically blend for 5 minutes. Apply generously to skin over affected area. The same ratios apply to larger batches. The chitosan-oil-water-mineral composition permits the ingredients to cross tissue barriers to effect skin, connective tissue, tendon, ligaments, cartilage and bone to relieve pain, stop inflammation and heal inflamed underlying tissue. The respective components of the chitosan-oil-water-mineral composition will not cross the pericutaneous tissue barriers alone.
FIELD: medicine, narcology. SUBSTANCE: therapy course consists of four stages. During the first stage it is necessary to reveal patient's mood and attitude towards the problem to conceive her/him in curability. At the second stage heroin intake should be excluded to conduct body detoxication for 5-6 d. During the third stage in case of negative test to opiates a patient is injected the blocking agent of opiate receptors along with simultaneous intake of placebo preparation which imitates additional blocking agent of opiate receptors and causes aversion in response to opiate introduction, duration is 1-3 mo. At the fourth stage a patient should be prepared to overcome difficulties of future traveling to Himalayas. After the flight, during 6-7 d during acclimatization and psychological adaptation in dzen- buddhism commune at 1200 m above sea level a patient should eat low-calorie food along with daily practice of dynamic meditation. After that, it is necessary to climb at 5000-6000 m above sea level. EFFECT: higher efficiency of therapy. 4 cl, 2 ex
Low-grade gliomas (LGGs) are a heterogeneous group of tumors with an average 10-year survival rate of 40%-55%. Current treatment options include chemotherapy, radiotherapy, and gross total resection (GTR) of the tumor. The extent of resection (EOR) plays an important role in improving surgical outcomes. However, the major obstacle in treating low-grade gliomas is their diffused nature and the presence of residual cancer cells at the tumor margins post resection. Cold Atmospheric Plasma (CAP) has shown to be effective in targeted killing of tumor cells in various glioma cell lines without affecting non-tumor cells through Reactive Oxygen and Nitrogen Species (RONS). However, no study on the effectiveness of CAP has been carried out in LGG tissues till date. In this study, we applied helium-based CAP on tumor tissues resected from LGG patients. Our results show that CAP is effective in promoting RONS accumulation in LGG tissues when CAP jet parameters are set at 4 kV voltage, 5 min treatment time and 3 lpm gas flow rate. We also observed that CAP jet is more effective in thinner slice preparations of tumor as compared to thick tumor samples. Our results indicate that CAP could prove to be an effective adjunct therapy in glioma surgery to target residual cancer cells to improve surgical outcome of patients with low-grade glioma.
Group 2:Control group. All subjects will have conventional aligner treatment with aligners replaced every 7 days, and standard in-office visits every 8 weeks.
FIELD: medicine.SUBSTANCE: endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. The residual gel is taken off. An active portion of one needle electrode is intraocularly applied on the scleral bed in parallel with the retinotomy border at 0.5-0.7 mm. The second electrode is applied in parallel to the first one at 3-4 mm to the centre of the scleral bed. That is followed by performing an electrochemical lysis (ECL) at the current intensity of 5 mA for 10 seconds. The electrodes are gradually moved along the scleral bed surface first circle-wise, in parallel to the retinotomy border, then from the periphery to the centre. The ECL covers the entire area of the scleral bed at the current intensity of 5 mA for 10-15 seconds in each position of the electrodes. That is followed by intraocular photodynamic therapy (PDT) along the entire area of the scleral bed with involving the 1.5 mm surrounding tissues. The patient is exposed to laser light at a wave length of 662 nm, power density of 60 J/cm, by fields of 4 mm in diameter, circle-wise from the periphery to the centre, and involving the adjoining fields by 5% of the area.EFFECT: avoiding the tumour cells remained viable on the scleral bed after the endoresection of the intraocular new growth, eliminating recurrences of tumours and metastases in the remote postoperative period.1 ex
BACKGROUND: Migraine and dizziness often coexist, with vestibular migraine (VM) presenting with vestibular symptoms and headaches. Calcitonin gene-related peptide (CGRP) may be involved in motion-induced symptoms; however, studies on the use of anti-CGRP monoclonal antibodies (mAbs) for the treatment of VM have yielded conflicting results. This study aimed to clarify the effectiveness of anti-CGRP mAbs in VM treatment.
METHODS: This retrospective observational cohort study, conducted between 1 January 2021 and 31 March 2023, assessed 12 Japanese patients with VM who were treated with anti-CGRP mAbs (CGRP group) for 6 months and 11 Japanese patients who received standard of care for VM and served as controls. Clinical questionnaires and equilibrium tests were administered, with primary outcomes including changes in Dizziness Handicap Inventory (DHI) scores compared with baseline values. Objective variables included the DHI score and explanatory variables included demographic data, balance test results, head-up tilt (HUT) test results, vestibular test results and questionnaire survey results. Analysis of variance was used to assess the treatment effects of anti-CGRP mAbs, and multivariate regression analysis was performed to identify mAb responders.
RESULTS: After 6 months, the CGRP group showed significant improvements in DHI scores [0 versus 6 months, odds ratio (95% confidence interval): 22.01 (0.13-43.88)] and number of vertigo/dizziness attacks per month [0 versus 6 months: 10.28 (2.80-17.76)]. No significant difference was observed in the control group [DHI scores, 0 versus 6 months: 0.65 (-26.84 to 28.14); number of vertigo/dizziness attacks per month, 0 versus 6 months: - 8.07 (- 23.77 to 7.62)]. Multivariate regression analysis showed that autonomic function at baseline was associated with mAb response in patients [β estimates (95% confidence interval): 3.63 (0.21-7.06)].
CONCLUSIONS: Treatment with anti-CGRP mAbs was more effective than conventional treatment in preventing migraine in patients with VM. While the identified factors associated with treatment responsiveness offer valuable insights into personalised treatment approaches, further prospective studies are warranted to validate the findings due to our study's retrospective design and limited sample size.
BACKGROUND: Prior studies have suggested a potential relationship between osteoporosis and sarcopenia, both of which can present symptoms of compromised mobility. Additionally, fractures among the elderly are often considered a common outcome of both conditions. There is a strong correlation between fractures in the elderly population, decreased muscle mass, weakened muscle strength, heightened risk of falls, and diminished bone density. This study aimed to pinpoint crucial diagnostic candidate genes for osteoporosis patients with concomitant sarcopenia.
METHODS: Two osteoporosis datasets and one sarcopenia dataset were obtained from the Gene Expression Omnibus (GEO). Differential expression genes (DEGs) and module genes were identified using Limma and Weighted Gene Co-expression Network Analysis (WGCNA), followed by functional enrichment analysis, construction of protein-protein interaction (PPI) networks, and application of a machine learning algorithm (least absolute shrinkage and selection operator (LASSO) regression) to determine candidate hub genes for diagnosing osteoporosis combined with sarcopenia. Receiver operating characteristic (ROC) curves and column line plots were generated.
RESULTS: The merged osteoporosis dataset comprised 2067 DEGs, with 424 module genes filtered in sarcopenia. The intersection of DEGs between osteoporosis and sarcopenia module genes consisted of 60 genes, primarily enriched in viral infection. Through construction of the PPI network, 30 node genes were filtered, and after machine learning, 7 candidate hub genes were selected for column line plot construction and diagnostic value assessment. Both the column line plots and all 7 candidate hub genes exhibited high diagnostic value (area under the curve ranging from 1.00 to 0.93).
CONCLUSION: We identified 7 candidate hub genes (PDP1, ALS2CL, VLDLR, PLEKHA6, PPP1CB, MOSPD2, METTL9) and constructed column line plots for osteoporosis combined with sarcopenia. This study provides reference for potential peripheral blood diagnostic candidate genes for sarcopenia in osteoporosis patients.
Here, we characterized the p.Arg583His (R583H) Kv7.1 mutation, identified in two unrelated families suffered from LQT syndrome. This mutation is located in the HС-HD linker of the cytoplasmic portion of the Kv7.1 channel. This linker, together with HD helix are responsible for binding the A-kinase anchoring protein 9 (AKAP9), Yotiao. We studied the electrophysiological characteristics of the mutated channel expressed in CHO-K1 along with KCNE1 subunit and Yotiao protein, using the whole-cell patch-clamp technique. We found that R583H mutation, even at the heterozygous state, impedes IKs activation. Molecular modeling showed that HС and HD helixes of the C-terminal part of Kv7.1 channel are swapped along the C-terminus length of the channel and that R583 position is exposed to the outer surface of HC-HD tandem coiled-coil. Interestingly, the adenylate cyclase activator, forskolin had a smaller effect on the mutant channel comparing with the WT protein, suggesting that R583H mutation may disrupt the interaction of the channel with the adaptor protein Yotiao and, therefore, may impair phosphorylation of the KCNQ1 channel.
In the first stage, five healthy human subjects will receive a microdose (10 µg) of \[11C\]MPC6827, immediately followed by whole body PET/CT to determine dosimetry and perform an initial safety evaluation of the radiotracer. A dose of 20 mCi \[11C\]MPC6827 will be administered and serial whole body PET scans will be acquired up to 2 hours post injection.
CHEMET (succimer) is an orally active, lead chelating agent. The chemical name for succimer is meso2, 3-dimercaptosuccinic acid (DMSA). Its empirical formula is C4H6O4S2 and molecular weight is 182.2. The meso-structural formula is:

Succimer is a white crystalline powder with an unpleasant, characteristic mercaptan odor and taste.

Each CHEMET opaque white capsule for oral administration contains medicated beads with 100 mg of succimer and the following inactive ingredients: povidone, sodium starch glycolate, and sugar spheres. The capsule shell contains benzyl alcohol, butylparaben, edetate calcium disodium, gelatin, methylparaben, propylparaben, sodium lauryl sulfate, sodium propionate, titanium dioxide, and is imprinted with edible black ink.
Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
It is imperative to have effective treatment strategies for PAD which can maintain the patency of arteries. The current standard of care for PAD is angioplasty which includes usage of drug coated balloons (DCB). Paclitaxel is the only anti-proliferative drug available in all currently available DCB technology. Sirolimus is another highly effective anti-proliferative drug of immense potential as demonstrated by superior results in Sirolimus drug eluting stents in coronary disease. The physical properties of Sirolimus have made it challenging for it to be similarly applied to DCB technology and it is only due to recent advances in nanotechnology that it is now possible to develop Sirolimus coated balloons (SCB), which is the study device used in this study. The study device allows delivery and deposition of sirolimus to the arterial wall. By applying this agent into lesions in peripheral arterial disease, this study aim to effectively reduce neointimal hyperplasia, and therefore prolong the patency of the artery and improve our limb salvage rates for PAD and CLI patients. Subjects will be followed up in the clinic at 6 month, 12 month, and 24 month post-intervention to assess primary and secondary outcome of safety and efficacy.
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Disclosed is a product and method for transplanting biological fluids into a host animal (including humans) that have been collected from donor animals. These biological fluids have been purified and processed so that they are acellular, sterile, pathogen free, and a form that can be stored for considerable periods of time without degradation. In one embodiment, synovial fluid is harvested from a large number of donors to produce the transplantation compound. Donor fluid is collected from a number of joints per animal, and initially screened for obvious abnormalities (clarity, color, viscosity etc.) and accepted or rejected on a joint-by-joint basis at the time of collection. The collected fluid is frozen in the field. Once in a laboratory setting, the fluid is warmed and spun down in a centrifuge. The supernate is collected, filtered, and mixed in large batches while the permeate is discarded. The supernate is re-frozen, lyophilized (freeze-dried) to form a cake and packaged as an individual dose under vacuum. The product is sterile, stable, has a long shelf life and can be readily reconstituted and injected into a joint.